Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT04310189 Completed - Atopic Dermatitis Clinical Trials

The Role of IL-22/IL-22BP Axis in Atopic Dermatitis

DA/IL-22BP
Start date: December 2, 2020
Phase: N/A
Study type: Interventional

Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserves further investigation. The main objective of this study is to better understand the potential protective role of IL-22BP through the assessment of its expression at the Messenger Ribonucleic Acid (mRNA) and protein levels in skin and serum which will be correlated to the severity of the diseases and through the identification of its cellular sources in lesions. The results of this study will help to correctly interpret the levels of IL-22 in AD and will potentially allow identifying biomarkers for patient stratification and predicting clinical outcomes to targeted therapeutic agents.

NCT ID: NCT04308889 Completed - Inflammation; Skin Clinical Trials

Pro-Resolving Mediators in Acute Inflammation in Humans

Start date: July 2, 2018
Phase: Early Phase 1
Study type: Interventional

The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.

NCT ID: NCT04306965 Completed - Atopic Dermatitis Clinical Trials

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses.

NCT ID: NCT04295824 Completed - Clinical trials for Atopic Dermatitis Eczema

Skin Pathology Assessment With Optical Technologies

SPOT
Start date: August 6, 2020
Phase:
Study type: Observational

The Skin Pathology assessment with Optical Technologies (SPOT) study aims to assess the feasibility of recently developed light-based skin imaging tools such as Optical Coherence Tomography (OCT) for the study of eczema (dermatitis [AD]). Tools such as OCT have enabled us to see beneath the skin surface, allowing us to see changes in our skin which are hidden and impossible to assess by eye, simply by shining harmless light into the skin. The investigators want to understand what these changes represent in the broader context of eczema. To do this, the investigators would like to recruit 60 volunteers who have a range of different eczema severities. The investigators would also like to recruit 20 healthy volunteers, who have never suffered from eczema. All volunteers would be aged between 11 and 60. The study is based at the Royal Hallamshire Hospital in Sheffield, with consent and sample-collection taking place at either the hospital's Clinical Research Facility or the Sheffield Children's Hospital. The study consists of a single main visit, which is expected to take approximately 3 hours, and a short follow up visit 2-4 weeks later. During the main study visit, the investigators will collect a range of measurements from the inner elbows and cheeks using harmless topical probes (Including OCT). These measurements include information about the skin's layers, blood flow, composition, water loss, acidity and redness. The investigators will also collect some samples, including tape-strips, a saliva sample and blood samples. For adult participants the investigators will also collect 2-4 skin biopsies from the inner elbows, which involves removing small pieces of skin under a local anaesthetic. It is our hope that by demonstrating the advantages of new harmless imaging techniques, the investigators can reduce the need for invasive procedures in the future. Long term, this may help us to improve the way healthcare professionals monitor and treat eczema.

NCT ID: NCT04287608 Completed - Atopic Dermatitis Clinical Trials

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Start date: March 10, 2021
Phase:
Study type: Observational

The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.

NCT ID: NCT04271514 Completed - Atopic Dermatitis Clinical Trials

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Start date: August 12, 2019
Phase: Phase 1
Study type: Interventional

This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.

NCT ID: NCT04271007 Completed - Atopic Dermatitis Clinical Trials

Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates

LB2001
Start date: November 23, 2020
Phase: Phase 4
Study type: Interventional

Atopic dermatitis is a chronic disease, with outbreaks, predominant in childhood, whose main symptom is pruritus of variable intensity and signs of cutaneous xerosis and eczematous pattern lesions. In this context, the present study aims to evaluate a comparative way of Topison drugs in reducing transepidermal water loss, improving skin hydration and comfort in participants with atopic dermatitis.

NCT ID: NCT04261387 Completed - Clinical trials for Radiation Dermatitis

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

Start date: January 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days and will be followed up for 2 months after the completion of study treatment. Subject in Part 2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind treatment) for qd topical application for 28 days and will be followed up for 2 months after the completion of study treatment.

NCT ID: NCT04256174 Completed - Atopic Dermatitis Clinical Trials

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Start date: June 15, 2020
Phase: Phase 1
Study type: Interventional

A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis

NCT ID: NCT04250350 Completed - Atopic Dermatitis Clinical Trials

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

ADore
Start date: February 11, 2020
Phase: Phase 3
Study type: Interventional

This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.